Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 21, 2007. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The filing reports a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. Consequently, there was an increase in the notional allocation of Ordinary Share ADRs on May 18, 2007, at a price of $57.71 per share for the following individuals:
- Mrs C Bruck Slaoui: 2 shares
- Dr R G Greig: 2 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Facts for Investor Verification
- Transaction Date: May 18, 2007
- Transaction Price: $57.71 per GSK Ordinary Share ADR
- Involved Parties: Mrs C Bruck Slaoui and Dr R G Greig
- Transaction Type: Increase in notional allocation within the US Retirement Savings Plan
- Reporting Date: May 21, 2007